Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells

British Journal of Cancer

Volumn 111, Issue 5, 2014, Pages 874-882

  Valenzuela, M ^a,d   Glorieux, C ^a   Stockis, J ^b   Sid, B ^a   Sandoval, J M ^a   Felipe, K B ^a,e   Kviecinski, M R ^a   Verrax, J ^a   Calderon, P Buc ^a,c  

^a Louvain Drug Research Institute   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c UNIVERSIDAD ARTURO PRAT   (Chile)

^d UNIVERSITY OF CHILE   (Chile)

^e FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

acute promyelocytic leukaemia; all trans retinoic acid; arsenic trioxide; GSH; HO 1; Nrf2

Indexed keywords

ARSENIC TRIOXIDE; FERRITIN; HEME OXYGENASE 1; RETINOIC ACID; TRANSCRIPTION FACTOR NRF2; TRYPAN BLUE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL; CANCER SURVIVAL; DRUG CYTOTOXICITY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MONOTHERAPY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ARSENICALS; CELL SURVIVAL; DRUG SYNERGISM; GLUTATHIONE; HEME OXYGENASE-1; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NF-E2-RELATED FACTOR 2; OXIDES; RECEPTORS, RETINOIC ACID; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 84906939255     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.380     Document Type: Article

References (43)

1. Ablain J, Leiva M, Peres L, Fonsart J, Anthony E, de The H (2013) Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. J Exp Med 210: 647-653.
2. Alarifi S, Ali D, Alkahtani S, Siddiqui MA, Ali BA (2013) Arsenic trioxidemediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells. Onco Targets Ther 6: 75-84.
3. Apfel C, Bauer F, Crettaz M, Forni L, Kamber M, Kaufmann F, LeMotte P, Pirson W, Klaus M (1992) A retinoic acid receptor alpha antagonist selectively counteracts retinoic acid effects. Proc Natl Acad Sci USA 89: 7129-7133.
4. Chen Y, Lin-Shiau S, JK LIN (1998) Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 177: 324-333.
5. Chendamarai E, Balasubramanian P, George B, Viswabandya A, Abraham A, Ahmed R, Alex AA,Ganesan S, Lakshmi KM, SitaramU,Nair SC, ChandyM, Janet NB, Srivastava VM, Srivastava A, Mathews V (2012) Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy. Blood 119: 3413-3419.
6. Chou C, Jie C, KenedyA, Jones RJ, TrushMA,Dang CV (2004) Role ofNADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci USA 101: 4578-4583.
7. Davison K, Cote S, Mader S, Miller WH (2003) Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 17: 931-940.
8. Duprez E, Benoit G, Flexor M, Lillehaug JR, Lanotte M (2000) A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities. Leukemia 14: 255-261.
9. Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T (2011) Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood 118: 1600-1609.
10. Gozzelino R, Jeney V, Soares MP (2010) Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 50: 323-354.
11. Gupta K, Chakrabarti A, Rana S, Ramdeo R, Roth BL, Agarwal ML, Tse W, Agarwal MK, Wald DN (2011) Securinine, a myeloid differentiation agent with therapeutic potential for AML. PLoS One 6: e21203.
12. Heasman SA, Zaitseva L, Bowles KM, Rushworth SA, Macewan DJ (2011) Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. Oncotarget 2: 658-668.
13. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY (1998) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572.
14. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF. Australasian Leukaemia and Lymphoma Group (2012) All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 120: 1570-1580.
15. Isbister GK, Dawson AH, Whyte IM (2004) Arsenic trioxide poisoning: a description of two acute overdoses. Hum Exp Toxicol 23: 359-364.
16. Kamimura T, Miyamoto T, Harada M, Akashi K (2011) Advances in therapies for acute promyelocytic leukemia. Cancer Sci 102: 1929-1937.
17. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nuñez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G. Nomenclature Committee on Cell Death 2009 (2009) Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ 16: 3-11.
18. Lang E, Grudic A, Pankiv S, Bruserud O, Simonsen A, Bjerkvig R, Bjørås M, Bøe SO (2012) The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling. Blood 120: 847-857.
19. Lau A, Zheng Y, Tao S, Wang H, Whitman SA, White E, Zhang DD (2013) Arsenic inhibits autophagic flux activating the Nrf2-Keap1 pathway in a p62-dependent manner. Mol Cell Biol 33: 2436-2446.
20. Ma Q (2012) Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53: 401-426.
21. Marasca R, Zucchini P, Galimberti S, Leonardi G, Vaccari P, Donelli A, Luppi M, Petrini M, Torelli G (1999) Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. Haematologica 84: 963-968.
22. Miller Jr. WH, Schipper HM, Lee JS, Singer J, Waxman S (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62: 3893-3903.
23. Morales AA, Gutman D, Cejas PJ, Lee KP, Boise LH (2009) Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. J Biol Chem 284: 12886-12895.
24. Nakamura S, Nagano S, Nagao H, Ishidou Y, Yokouchi M, Abematsu M, Yamamoto T, Komiya S, Setoguchi T (2013) Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI transcription via DNA damage accumulation. PLoS One 8: e69466.
25. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin TT, Yu VL, Miller DK (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43.
26. Park JH (2012) ATRA plus arsenic gets another "A" in APL. Blood 120: 1535-1536.
27. Patatanian E, Thompson DF. Retinoic acid syndrome: a review (2008) J Clin Pharm Ther 33: 331-338.
28. Rahman I, Kode A, Biswas SK (2006) Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 1: 3159-3165.
29. Rushworth SA, MacEwan DJ (2011) The role of Nrf2 and cytoprotection in regulating chemotherapy resistance of human leukemia cells. Cancers 3: 1605-1621.
30. Rushworth SA, Zaitseva L, Langa S, Bowles KM, MacEwan DJ (2010) FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism. Oncotarget 1: 359-366.
31. Saeed S, Logie C, Stunnenberg HG, Martens JH (2011) Genome-wide functions of PML-RARalpha in acute promyelocytic leukaemia. Br J Cancer 104: 554-558.
32. Sekeres MA, Maciejewski JP, Erba HP, Afable M, Englehaupt R, Sobecks R, Advani A, Seel S, Chan J, Kalaycio ME (2011) A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer 117: 1253-1261.
33. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett Jr RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH (2012) A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118: 2507-2515.
34. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360.
35. Tallman MS, Altman JK (2009) How I treat acute promyelocytic leukemia. Blood 114: 5126-5135.
36. Valenzuela M, Perez-Perez G, Corvalan AH, Carrasco G, Urra H, Bravo D, Toledo H, Quest AF (2010) Helicobacter pylori-induced loss of the inhibitor-of-apoptosis protein survivin is linked to gastritis and death of human gastric cells. J Infect Dis 202: 1021-1030.
37. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951.
38. Wang H, Liu K, Geng M, Gao P, Wu X, Hai Y, Li Y, Li Y, Luo L, Hayes JD, Wang XJ, Tang X (2013) RXR alpha inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2. Cancer Res 73: 3097-3108.
39. Wang L, Weng CY, Wang YJ, Wu MJ (2011) Lipoic acid ameliorates arsenic trioxide-induced HO-1 expression and oxidative stress in THP-1 monocytes and macrophages. Chem Biol Interact 190: 129-138.
40. Wang XJ, Hayes JD, Henderson CJ, Wolf CR (2007) Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc Natl Acad Sci USA 104: 19589-19594.
41. Wetzler M, Andrews C, Ford LA, Tighe S, Barcos M, Sait SN, Block AW, Nowak NJ, Baer MR, Wang ES, Baumann H (2011) Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged o60 years with acute myeloid leukemia. Cancer 117: 4861-4868.
42. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de Thé H, Chen SJ, Chen Z (2010) Arsenic trioxide controls the fate of the PML-RARalphaoncoprotein by directly binding PML. Science 328: 240-243.
43. Zhou DC, Kim SH, Ding W, Schultz C, Warrell Jr. RP, Gallagher RE (2002) Frequent mutations in the ligand-binding domain of PML-RAR alpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 99: 1356-1363.